Perspectives on HCV: Current Therapeutic Regimens and Drug-Drug Interactions.
- Published in:
- Clinical Pharmacology in Drug Development, 2017, v. 6, n. 2, p. 147, doi. 10.1002/cpdd.338
- By:
- Publication type:
- Article
Works matching IS 2160763X AND DT 2017 AND VI 6 AND IP 2
Results: 14
1
2
Mechanisms and Consequences of Drug-Drug Interactions.
- Published in:
- Clinical Pharmacology in Drug Development, 2017, v. 6, n. 2, p. 118, doi. 10.1002/cpdd.339
- By:
- Publication type:
- Article
3
Omics for Understanding the Gut-Liver-Microbiome Axis and Precision Medicine.
- Published in:
- Clinical Pharmacology in Drug Development, 2017, v. 6, n. 2, p. 176, doi. 10.1002/cpdd.310
- By:
- Publication type:
- Article
4
Intrahepatic Sampling for the Elucidation of Antiviral Clinical Pharmacology.
- Published in:
- Clinical Pharmacology in Drug Development, 2017, v. 6, n. 2, p. 169, doi. 10.1002/cpdd.311
- By:
- Publication type:
- Article
5
Liver Disease and Fibrosis Assessment in Substance Use-Related Disorders.
- Published in:
- Clinical Pharmacology in Drug Development, 2017, v. 6, n. 2, p. 164, doi. 10.1002/cpdd.312
- By:
- Publication type:
- Article
6
Pharmacokinetic Considerations for Combining Antiretroviral Therapy, Direct-Acting Antiviral Agents for Hepatitis C Virus, and Addiction Treatment Medications.
- Published in:
- Clinical Pharmacology in Drug Development, 2017, v. 6, n. 2, p. 135, doi. 10.1002/cpdd.313
- By:
- Publication type:
- Article
7
Drug- and Drug Abuse-Associated Hyperbilirubinemia: Experience With Atazanavir.
- Published in:
- Clinical Pharmacology in Drug Development, 2017, v. 6, n. 2, p. 140, doi. 10.1002/cpdd.314
- By:
- Publication type:
- Article
8
Asunaprevir: An HCV Protease Inhibitor With Preferential Liver Distribution.
- Published in:
- Clinical Pharmacology in Drug Development, 2017, v. 6, n. 2, p. 195, doi. 10.1002/cpdd.315
- By:
- Publication type:
- Article
9
Drug-Drug Interactions and Diagnostics for Drug Users With HIV and HIV/HCV Coinfections: Introduction.
- Published in:
- Clinical Pharmacology in Drug Development, 2017, v. 6, n. 2, p. 108, doi. 10.1002/cpdd.316
- By:
- Publication type:
- Article
10
Cure Strategies for Hepatitis B Virus: The Promise of Immunotherapy.
- Published in:
- Clinical Pharmacology in Drug Development, 2017, v. 6, n. 2, p. 186, doi. 10.1002/cpdd.317
- By:
- Publication type:
- Article
11
Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir: Drug Interactions With Antiretroviral Agents and Drugs forSubstance Abuse.
- Published in:
- Clinical Pharmacology in Drug Development, 2017, v. 6, n. 2, p. 201, doi. 10.1002/cpdd.327
- By:
- Publication type:
- Article
12
Assessment of Hepatic Impairment and Implications for Pharmacokinetics of Substance Use Treatment.
- Published in:
- Clinical Pharmacology in Drug Development, 2017, v. 6, n. 2, p. 206, doi. 10.1002/cpdd.336
- By:
- Publication type:
- Article
13
Current Concepts in Methadone Metabolism and Transport.
- Published in:
- Clinical Pharmacology in Drug Development, 2017, v. 6, n. 2, p. 125, doi. 10.1002/cpdd.326
- By:
- Publication type:
- Article
14
Issue Information.
- Published in:
- Clinical Pharmacology in Drug Development, 2017, v. 6, n. 2, p. 103, doi. 10.1002/cpdd.301
- Publication type:
- Article